Skip to content

Biz News Today

Business News – Direct Source News

  • Home
  • Business News Videos
    • International/National News Videos
  • Directory
  • Links PRs
  • REITS
  • About
  • Contact
    • Sitemap

EMA Validates Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

  • Home
  • 2021
  • August
  • 17
  • EMA Validates Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Original Source

On August 17, 2021

Post navigation

Previous PostDollar General Commits $250,000 Donation to American Red Cross
Next PostBristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma

Related Post

May 25, 2022
  • Business News

Boeing, NASA Complete First Starliner Space Station Flight Test

May 25, 2022
  • Business News

Northrop Grumman Australia Announces Tech Showcase Winners

May 25, 2022
  • Business News

IQVIA CFO Ron Bruehlman to Speak at Jefferies Healthcare Conference on June 10, 2022

Copyright © All right reserved
Newslist Created By Rise Themes

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219